Rosetta Genomics (ROSG) Reports Q4 Loss Per Share of $0.14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Aegis Capital Still Positive on Rosetta Genomics (ROSG) Following Q4 Results; Nudges Ests Higher
March 24, 2016 11:41 AM EDTAegis Capital affirms Rosetta Genomics (NASDAQ: ROSG) with a Buy rating and $3.50 price target after ROSG reported Q4/FY15 results earlier Thursday.
Analyst Robert LeBoyer commented, We believe this quarterly report confirms our belief that the company has high-value cancer diagnostic... More
Rosetta Genomics (ROSG) Files $75M Mixed Shelf
March 23, 2016 4:48 PM EDTRosetta Genomics (NASDAQ: ROSG) filed a registration with the U.S. SEC to sell, from time to time, up to $75 million worth of mixed securities.
... More